6/27/23, 11:49 PM BrigHTN (baxdrostat 1 mg) Pathway Feedback Search Clinical Topics Home Studies BrigHTN (baxdrostat 1 mg) BrigHTN (baxdrostat 1 mg) Disease Hypertension Trial question What is the role of mid-dose baxdrostat in patients with treatment-resistant hypertension? Study design Multi-center Double blinded RCT Population Characteristics of study participants 43.0% female N = 139 57.0% male 139 patients (60 female, 79 male) Inclusion criteria: patients who had treatment-resistant hypertension, with BP 130/80 mmHg, and who were receiving stable doses of at least three antihypertensive agents, including a diuretic Key exclusion criteria: mean seated systolic BP of at least 180 mmHg or diastolic BP of at least 110 mmHg; an eGFR of < 45 mL/min/1.73 m ; uncontrolled diabetes Interventions N=70 baxdrostat (at a dose of 1 mg daily for 12 weeks) N=69 placebo (matching placebo for 12 weeks) Primary outcome Reduction in mean systolic blood pressure at week 12 17.5 mmHg 17.5 https://web.pathway.md/studies/recPwhVPcTBp2dPnA 1/2 6/27/23, 11:49 PM BrigHTN (baxdrostat 1 mg) Pathway 13.1 mmHg 9.4 8.8 mmHg 4.4 mmHg Significant increase 0.0 mmHg Baxdrostat Placebo Significant increase in reduction in mean systolic BP at week 12 (17.5 mmHg vs. 9.4 mmHg; AD 8.1 mmHg, 95% CI 2.8 to 13.5) Safety outcomes No significant difference in adverse events. Conclusion In patients who had treatment-resistant hypertension, with BP 130/80 mmHg, and who were receiving stable doses of at least three antihypertensive agents, including a diuretic, baxdrostat was superior to placebo with respect to reduction in mean systolic BP at week 12. Reference Mason W Freeman, Yuan-Di Halvorsen, William Marshall et al. Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension. N Engl J Med. 2023 Feb 2;388(5):395-405. Open reference URL https://web.pathway.md/studies/recPwhVPcTBp2dPnA 2/2